Correction: Novel fusion protein PK5-RL-Gal-3 C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity

Correction: BMC Cancer 23, 154 (2023)

10.1186/s12885-023-10608-9

Following publication of the original article [1], the authors identified an error in Fig. 3F. The representative tube formation figure of lactose group was wrong. The correction does not have any effect on the results and conclusions of the article. The corrected Fig. 3 is given in this correction article and the original article [1] is corrected.

Fig. 3.

PK5-RL-Gal-3 C inhibits angiogenesis in vivo and in vitro. Tube formation assay in vitro was performed to determine the inhibitory effect of rPK5-RL-Gal-3 C on angiogenesis according to the materials and methods. A and B rPK5-RL-Gal-3 C exhibited stronger inhibitory action than E25, rPK5 and rGal-3 C on tube formation in vitro. After treated with H1/EEV and H1/EEV-PK5-RL-Gal-3 C nanoparticles, the tumors were removed and stained by CD31 antibody using IHC. C and D H1/EEV-PK5-RL-Gal-3 C treatment down-regulated the expression of CD31 in tumor tissues. VEGF-induced matrigel plug assay in vivo were performed to determine the inhibitory effect of rPK5-RL-Gal-3 C on angiogenesis according to the materials and methods. E rPK5-RL-Gal-3 C exhibited stronger inhibitory action than rPK5 and rGal-3 C in VEGF-induced matrigel plug assay model in vivo. F and G lactose partially blockaded the inhibitory action of rPK5-RL-Gal-3 C but not sucrose. Significant differences are denoted by * for p < 0.05, ** for p < 0.01, *** for p < 0.001 and ns, no significance